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SYNTHESIS OF NOVEL CYSTEINE PEPTIDE NUCLEIC ACID (CPNA) 
MEHUL J. AJMERA 
ABSTRACT 
 
 Many diseases are caused due to abnormalities in production of specific protein. 
Across this protein the conventional lock and key mechanism shows binding at the 
specific cites of protein. However use of antisense technology can prevent formation of 
protein. It does so by binding to mRNA and prevents transcription. The structural 
modifications lead to synthetic molecules with 18-mer units which show significant 
improvement in binding properties, this gives birth to a new class of oligomers called 
Peptide Nucleic Acid (PNA). We herein report cysteine based PNA called CPNA.
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CHAPTER 1 
INTRODUCTION 
 
1.1-Introduction to Peptide Nucleic Acid 
One of the most important processes in the human body is the controlled 
production of specific proteins. The under or over production of these proteins at wrong 
time in cell cycle can lead to many different types of diseases. One way to modify this 
process is by antigene or antisense manipulation of protein production. In order to 
accomplish this task, it is vital to know the DNA sequence for each protein of interest so 
as to provide targets for new drugs.  This quest for novel treatments opened the doors to 
the concept of Peptide Nucleic Acid (PNA).1   
PNA is an excellent mimic of DNA while maintaining certain substantial 
differences in its basic chemical structure that provide it certain immunities from the 
cell’s standard degradation mechanisms.  Also, it has displayed high affinity binding with 
the double stranded DNA via Watson-Crick base pairing and from Hoogstein type base 
pairing in the major groove. 
Discovered by Nielsen et al. in 1991, peptide nucleic acids are chemically similar 
to DNA or RNA.  However, because PNA does not occur naturally in the body, it must 
be chemically synthesized for all biological research needs.  In a comparison of their 
basic structures, the backbone of DNA is comprised of deoxyribose sugar units while 
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RNA uses ribose sugars for its backbone.  On the other hand, the backbone of PNA is 
comprised of N-(2-aminoethyl)-glycine units which are linked by peptide bonds as shown 
in Figure 1.1 
 
                        Figure 1 – DNA and PNA Backbones 
 
PNA’s are acyclic, achiral neutral oligomers that are designed to resemble the 
backbone structure of DNA and RNA.  However, since PNA consists of a string of amino 
acid residues it begins with an N-terminus instead of a 5’ end and ends with a C-terminus 
instead of a 3’ end.  Another difference in structure is the fact that the purine and 
pyrimidine bases are linked to the PNA backbone via a methylene carbonyl group.  
Additionally, it has been shown that the binding between PNA/DNA is much stronger 
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than the binding seen between two antiparallel strands of DNA.  This is due to the 
electrostatic repulsions between the phosphate groups on each strand of DNA.  When this 
repulsive force is removed (as seen with the DNA/PNA binding), the two strands bind 
much more tightly.   
In recent years, peptide nucleic acids have allowed scientists to make significant 
advancements in molecular biology procedures, diagnostic assays and antisense therapy.  
When a PNA sequence is designed, it is extremely important to ensure high binding 
specificity with the complementary DNA strand.  This is because a mismatch between the 
PNA and DNA results in a much larger destabilizing force than a similar mismatch in the 
DNA/DNA pair.  This binding strength and specificity also applies to PNA/RNA 
duplexes.   
Some of the early studies preformed by Nielsen et al. have demonstrated that a 
PNA/DNA mismatch is more destabilizing than a DNA/DNA duplex mismatch.  When 
measuring the stability of any duplex (DNA/DNA, PNA/DNA etc.), one of the most 
common methods is to observe the melting temperature (Tm).2  For the DNA/DNA 
duplex, the average ∆Tm was about 110C while the average ∆Tm for the PNA/DNA duplex 
was 150C.  This higher value of ∆Tm for the PNA/DNA complex indicates that it does in 
fact have a greater degree of stability than the DNA/DNA duplex.  The salt 
concentration’s effect on Tm was also observed for both sets of duplexes.  It can be seen 
in Figure 22 that the Tm for the PNA/DNA duplex (shown as blue circles) is not 
dependent on the salt concentration while the Tm for the DNA/DNA duplex (shown as 
pink squares) is highly dependent on the salt concentration.  
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Figure 2 - Thermal Stability Plot of PNA/DNA and DNA/DNA Duplexes 
 
When PNA hybridizes with DNA or RNA, it does so via Watson-Crick base 
pairing as shown in Figure 3.3 
 
                      
                           Figure 3 - Duplex of PNA with DNA or RNA 
 
When binding to DNA or RNA, it is possible for PNA to bind in either the 
parallel or the antiparallel orientation.  If it binds in the parallel orientation, the amine 
terminus of PNA binds to the 5’ end of either the DNA or RNA sequence, whereas 
binding in the antiparallel orientation consists of the 3’ end of either the DNA or RNA 
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sequence binding to the amine terminus of the PNA.  When the PNA oligonucleotide 
binds to double stranded DNA, it first invades the double stranded helix and then 
hybridizes to the target sequence thereby displacing the second DNA strand into a ‘D’ 
loop as shown in Figure 4.4,5,6. 
 
   
                             Figure 4 - Triplex between PNA-DNA2 
 
1.2-PNA as an Antisense Oligonucleotide 
During the past decade, many Biotech companies have displayed an interest in 
antisense oligonucleotides for the treatment and prevention of disease.  Antisense 
oligonucleotides are synthetic molecules that resemble pieces of single stranded DNA 
and incorporate any and/or all of the four bases.  These oligonucleotides can then be used 
to either inhibit or promote gene expression by binding directly to target DNA or RNA.  
Thus a particular sequence of antisense oligonucleotide could be designed specifically 
around a known mRNA transcript and then allowed to bind with that mRNA in order to 
control the production of a specific protein.  Also, a plethora of information about any 
gene could be obtained by synthesizing a vast library of complementary oligonucleotide 
sequences.  This is because of the hydrogen bonding that exists between the 
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complementary base pairs; it can provide necessary information for the design of an 
oligonucleotide which will target any gene with a known sequence.  Greater control over 
binding specificity could be obtained as a result of targeting a defective gene with such 
oligonucleotides which in turn would give birth to a new strategy of drug design.  
Antisense RNA can be described as a naturally occurring phenomenon in which 
the cell transcribes a strand of RNA which is complementary to a specific segment of 
mRNA.7,8 These antisense RNA strands hybridized to the mRNA thereby inhibiting gene 
expression.  As a way to keep these antisense RNA strands in check, certain enzymes 
have important key roles in the regulatory process of these antisense RNA strands.  It has 
been shown that studying a small portion of any gene can reveal its sequencing 
information thus providing scientists with the antisense sequence.   
The inhibition of gene expression through a natural process is already known for 
antisense RNA strands.  However, a similar natural system involving antisense DNA is 
unknown at this time.  In theory, the inhibition of a single gene target could be 
accomplished through the use of an oligomer 15 nucleotide bases in length that binds 
complementary to the mRNA strand in question.  
 
In 1978, Zamecnik and Stephenson discovered a new class of therapeutic agents 
called antisense oligonucleotides which specifically targeted mRNA.  This targeting can 
be seen in Figure 5.9 
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Figure 5 – Differences between Normal Cells, Antisense and Antigene Inhibited Ones 
 
These oligonucleotides bind to the mRNA strands via the Watson and Crick base pairing 
methods.  In doing so, this pairing inhibits the translation of disease causing proteins.  
This marked the beginning of a new strategy for the prevention of viral replication.  
Using this method, novel antiviral drug candidates could be designed to target and 
specifically bind to the viral RNA.  This new strategy can be seen as a combination of 
two current strategies.  The first being gene therapy which involves the introduction of a 
new gene into the affected individual, the second strategy is the conventional lock and 
key mechanism for drug discovery. 
In their research, Zamecnik and Stephenson successfully showed that antisense 
could be used to inhibit viral replication.10 using an antisense phosphodiester 
oligodeoxynucleotide (ODN), they observed that it bound to the mRNA strands of the 
Rous sarcoma virus which in turn inhibited replication.  Early studies into the mode of 
this type of inhibition prove that the binding between the mRNA strands and the ODN’s 
follow the antisense mechanism.  These studies used two types of ODN’s, control 
ODN’s, which were sequences that were not complementary for the target mRNA and 
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complementary ODN’s.  The specificity of binding was compared between the 
complementary ODNs and controls.  There were three different types of phosphate 
linkers used, one for each control strand and its complementary counterpart; 
phosphorothioate, phosphodiester and methyl phosphonate linkers.  These can be seen in 
Figure 6.11 
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                            Figure 6 – Different Phosphate Linkers 
 
Due to the fact that cellular RNA’s can have complex secondary and tertiary 
structures somewhat like proteins, binding complexities can been seen when the target 
antisense sequence is buried well within the secondary (or tertiary) structure.  One way to 
improve the binding specificity between an oligonucleotide and its target is to increase 
the number of complementary base pairs on the oligonucleotide.11,12,13. In doing so, the 
length of the oligonucleotide increases which can then present its own problems.  When 
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the oligonucleotide reaches a certain point, its binding specificity can be compromised 
due to its length.   
 
1.3-Mechanism of Antisense Inhibition 
In order for the oligodeoxynucleotide to inhibit any cellular process, it must bind 
to the mRNA.  This can occur in either the nucleus or the cytoplasm.  The inhibition of 
any gene can take place by two different mechanisms.  The first mechanism of inhibition 
involves the mRNA/DNA duplex.  Inside the nucleus, mRNA can be the initial sequence 
on which DNA is built.  Then, the RNase H enzyme moves in to remove the mRNA 
strands by degrading them which allows for the complementary DNA base pairs to be 
added to this newly formed strand thus providing you with double stranded DNA.13,14,15  
However, if ODN’s are present in the nucleus, then they will bind to the mRNA and 
prevent it from forming the new single stranded DNA.  This type of mechanism has the 
advantage that a single ODN can target many mRNA thus the therapeutic amount of this 
drug would be very small. 
The second mechanism of inhibition involves the formation of the ODN/RNA 
duplex.  Here, the single stranded ODN binds to the single stranded mRNA.  Since the 
ODN binds to the mRNA with such a high affinity, it sterically blocks any type of 
translation.16 when this occurs in the nucleus, transport across the nuclear membrane into 
the cytoplasm can be hindered due to the increased amount of sterics within this larger 
molecule.  If this occurs in the cytoplasm, the ODN’s will block the translation process 
thus preventing the formation of proteins.  However, the limitation to this mechanism is 
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that the ODN will have to physically bind to the mRNA molecule continuously.  In order 
to accomplish this task, three primary obstacles must be overcome.  First, the ODN must 
have enough cell permeability so as to cross the cell (and nuclear) membrane so that it 
can then bind to the mRNA.  Second, the ODN/RNA duplex must have a sufficiently 
long lifetime so as to prevent the translation of proteins.  Finally, the ODN should not 
disrupt the expression of non-targeted genes.  Since a non-targeted sequence will have 
some base pair mismatches, complexes with at least one mismatch should have a short 
half-life. 
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CHAPTER 2 
STRUCTURAL MODIFICATIONS 
 
2.1-Antisense Oligonucleotide Structural Modification 
The antisense ODN’s are molecules whose length is generally between 18 and 20 
base pairs long and possess an overall negative charge for every phosphate or 
phosphorothioate.  In order for the ODN’s to be effective drug molecules, they must 
display good pharmacokinetics as well as good pharmacodynamics.  The biggest 
challenge lies with the cellular uptake of these drug molecules because if these oligomers 
cannot readily enter the cells through normal processes (i.e. endocytosis, phagocytosis 
etc.), then they maybe useless as a novel drug.  Additional, there are other issues that 
must be addressed if these types of oligomers are to be considered successful drug 
candidates.  Such as the fact that they should be slowly degraded in the body, they should 
be highly bioavailable and once they have done their function they should be easily 
cleared from the body.17,18,19,20  With these facts in mind, studies have been preformed 
with various structural modifications of the ODN’s in order to determine how the 
modifications affect the oligomer’s properties.  Some of these structural changes include 
modification of the sugar backbone as well as modification of the phosphate linkages.  
Figure 7 shows the backbone structure of an oligonucleotide as well as the potential 
modification sites. 
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Over the past few decades, the modified antisense ODN’s have shown remarkable 
improvement in their cellular uptake as well as an increase in their specificity 
accompanied by a decrease in their toxicity. Several new classes of ODN’s have been 
developed by modifications of the phosphate bonds, modifying the way the bases are 
attached and also by modifying the oligonucleotide’s sugar backbone.  These resulting 
molecules have shown tremendous improvement in biological properties over their 
predecessors.  One such example of a current antisense ODN drug is Vitravene, which 
has been modified to include phosphothioate linkages in its backbone.21 However, there 
are other types of phosphate linkage modifications that can be incorporated into these 
oligonucleotides.  Some of these include phosphorothioates, phosphoramidates and 
phosphotriesters and can be seen in Figure 8. 
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When the sugar backbone was modified to include carbocycles or hexose,22 the 
oligomers did not show any significant improvement in their binding to mRNA.  
However, an increase in cell permeability has been observed for oligomers whose sugar 
backbone has been replaced with morpholine monomers.23 These monomers are linked 
with either a neutral carbamate-type linkage24 or with a phosphoromidate linkage.  
Locked Nucleic Acids (LNA)25 are another class of ODN’s that have shown good water 
solubility as well as excellent binding properties with complementary DNA.  Structurally, 
they contain one or more 2’-O and 4’-C-methylene β-D-ribofuranosyl nucleotide(s).  
Additionally, the 5 membered sugar backbone ring can be replaced with a six membered 
ring.  Doing so produces three different types of monomer backbones; cyclohexene 
nucleic acid, hexitol nucleic acid and cyclohexanyl nucleic acid.26 The hexitol nucleic 
acid can form enzymatically stable complexes with both DNA and RNA.  These various 
types of backbone modifications are shown in Figure 9. 
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2.2-Antiviral PNAs 
Many antisense oligonucleotides have been shown to inhibit viruses; the most 
commonly inhibited ones being HIV27, HSV1 & 228 and influenza.  This is because the 
viral genetic sequences are unique with respect to the host’s genetic sequences.  
Therefore, it should possible to design specific oligonucleotides that will bind 
preferentially and specifically to the viral mRNA without specific binding of the host 
mRNA.  PNA has already shown its antiviral properties by selectively inhibiting the 
reverse transcriptase enzyme, which is a key enzyme in the life cycle of HIV.  When the 
PNA oligomer binds to the RNA template, it prevents the reverse transcription process 
thereby preventing HIV infection.  This inhibition of the HIV virus’s replication cycle in 
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cultured cells has increased hopes that PNA can be used as an antiviral drug.  However, 
there are still obstacles to be overcome before PNA can be effectively used as an antiviral 
drug.  One such obstacle is the fact that the concentration of PNA that is required for this 
antiviral process is extremely high which indicates the need for either an alternate cell 
delivery system or for structural modifications of the PNA. 
 
2.3 - Antibacterial PNA 
The scope of PNA is not just limited to antiviral drugs; it can also be used in for 
many antibacterial applications.  This is because PNA can be specifically designed to 
enter any given bacteria and control its gene expression.  This gives PNA tremendous 
scope as antibacterial drug candidate.  For instance, antibacterial gene expression could 
be studied using antisense PNA.  The use of antisense technology as a tool for the 
creation of antibacterial drugs has gained momentum in the past decade.  Since the 
genome of any given bacteria is so small, it is easier to design and modify PNA so that it 
has improved binding and gene specific properties. 
 Structurally, bacteria are easier targets than eukaryotic cells because they lack 
internal organelles.  Therefore, since cellular distribution is not restricted and the 
bacterial genes are less complex, the PNA target is easier to access thus bacteria gene 
control should be easier to accomplish.  However, the PNA must first enter the bacteria 
which can be a problem due to the fact that bacteria protect themselves from their 
environment via a cell wall.  If the antisense PNA with specific binding properties has 
chemical permeability issues, it might not be able to penetrate the cell wall thus rendering 
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the PNA useless.  With this problem in mind, when mutant strains of E. coli cells with a 
defective lipopolysaccharide (LPS) layer were used, they showed a drastic increase in 
cellular uptake of PNA.  Additionally, both the binding properties and the length of the 
oligomer are key areas which affect the cell permeability.  Finally, the use of cell wall 
active peptides (KFFKFFKFFK) attached to the PNA can increase the cellular uptake.29 
Use of these peptides also shows antibacterial properties at low concentrations. 
 
2.4- PNA as Antigene 
PNA has also been shown to form a stable triplex complex with double stranded 
DNA as well as forming a strand displacement complex with double stranded DNA.  
When PNA is bound to DNA to form the triplex complex, the RNA polymerase cannot 
bind to create mRNA which in turn prevents the creation of a protein.  This type of 
inhibition of protein formation is called antigene inhibition.30,31  The binding efficiency 
of the gene targeting PNA must be high which leads to complete distortion of the DNA 
helix. 
 
2.5-Structural modification of Peptide Nucleic Acid 
As PNA’s applications as a drug began increasing, there was an increasing need 
to modify its structure to fit specific requirements for each unique application.  PNA has 
certain inherent limitations, two of which are cell permeability and solubility.  In order to 
circumvent these limitations, it was necessary to create structural modifications in the 
basic PNA monomer.  Two of the more common structural modifications are either a 
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change of ethylene diamine in the backbone or a nucleobase alteration.  The approach 
also includes introducing a chiral backbone from a conventional achiral one.  Doing so 
improves the binding selectivity between the PNA and the DNA as well as entropically 
favoring the duplex formation.  When a chiral backbone is used, the duplex gains stability 
from the conformational rigidity that is imparted from the chiral center.   
As a way to increase water solubility, positively charged species are put onto the 
PNA.  The location of this positively charged species can be at either the C terminus or 
the N terminus.  Generally, an oligomer’s water solubility can be increase by either 
incorporating a charged species or a functional group thereby increasing its overall 
polarity.  When negatively charged species such as phosphate analogs are incorporated, 
the oligomer’s water solubility generally increases.  However, strong electrostatic 
repulsions between the negatively charged oligomer and the negatively charged 
phosphates of the complementary DNA significantly reduce its binding affinity.  Figure 
10 shows two examples of phosphonate PNA’s.32 
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Figure 10 - Phosphonate PNA 
There have been several structural modifications done to PNA in order to obtain different 
desired properties; some of these include:-    
       Introducing the ether linkages within the PNA backbone.33,34  Doing so has shown to 
increase water solubility.  Examples of these linkages are shown in Figure 11. 
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Figure 11 - PNA with Ether Linkages 
Use of guanidium functional group.  The incorporation of this functional group has 
shown remarkable improvement in both water solubility and cell permeability.  Also, the 
binding efficiency with the complementary DNA is not compromised.  This has lead to 
various cationic PNA’s (DNG/PNA) which bind to complementary DNA and RNA.  One 
example is shown in Figure 12.35 
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Figure 12 - GPNA 
Another type of modification was made for the formation of heterodimeric analogs,36 
peptoid37 and retro-inverse.38  Structurally these compounds differ in their positioning of 
the carbonyl (CO) and amine (NH) groups as shown in Figure 13, 
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Figure 13 - Retro-inverso              Peptoid                       Heterodimeric analog of PNA 
 
A decrease in PNA/DNA hybridization was observed with both the peptoid and 
retroinverse type of structures.  The difference in the position of the CO group lead to 
geometrical modifications of the structures and proved less effective.  However in the 
case of the heterodimeric PNA, an improvement in the duplex formation was observed. 
 Modifications were also preformed by adding a methylene group in the aminoethyl 
part of backbone and also in the nucleobases.39 Examples of these modifications are 
shown in Figure 14. 
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Unfortunately, these structures have shown poor binding efficiency with complementary 
DNA and reduced thermal stability of the PNA/DNA duplex.   
 
2.6-Cellular uptake of PNA   
       Peptide nucleic acid has a neutral backbone.  As a result, it cannot be complexed 
with cationic lipids such as DNA or RNA.  Therefore, PNA’s cell permeability is 
decreased which in turn requires that a very high concentration of oligomer be used when 
treating a disease.  However, Corey and co-workers have shown that the in-vitro cell 
delivery method of PNA is possible when using a cationic lipid.40 This is because of the 
electrostatic force of attraction between the positively charged lipids and negatively 
charged phosphodiester of DNA and RNA.  When this cationic lipid fuses with the cell it 
allows the oligonucleotide to enter the cell.  This phenomenon is then used to inject the 
PNA into cell.  First, the PNA is allowed to hybridize to overlapping oligonucleotide, and 
then the cationic liquid is mixed with the hybridized complex which allows the PNA 
enter the cell.  Using this type of method, the desired cell permeability could be achieved 
by attaching certain peptide chains to the PNA. 
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Another approach to import PNA’s into the cell is by using transport vehicle like 
liposome’s.  At lower concentrations, PNA’s have demonstrated a certain ability to 
penetrate through the cell membrane.41,42  Finally, an increase in the intracellular PNA 
concentration has been shown to increase PNA’s cytotoxicity. 
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CHAPTER 3 
STRUCTURE AND SYNTHESIS OF MODIFIED PNA 
 
3.1-Design of potent Antisense drug 
        To design drug candidate’s using antisense mechanisms, it is important to consider 
the following hurdles. The first being poor cellular uptake. In order to reach to the 
cytoplasm or the nucleus the candidate must be able to cross the cell membrane. 
Secondly there should not be significant degradation once inside the cell. To inhibit a 
specific gene expression the candidate must have a high affinity and specificity to bind at 
the required site. To enhance specific binding properties, information regarding nucleic 
acid structure and thermodynamics is very important. A variety of structures could be 
obtained by changing position of the nucleobase, phosphodiester backbone and sugar. 
However for any of the designed molecules, the binding properties are governed by the 
Watson-Crick hydrogen bonding model. To increase the cell permeability, modifications 
of the phosphodiester backbone has been a very useful strategy. By the aid of molecular 
modeling, Dr Mark McLaughlin has an approach to replace the phosphodiester and sugar 
backbone with a chiral cysteine backbone introducing charged species to enhance cellular 
uptake. 
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3.2-Results & Discussions 
      The peptide designed by Dr McLaughlin has positively charged guanidine units as 
side chains. This species is introduced at the thiol by SN2 reaction. For the synthesis of 
PNA either Boc or Fmoc can be used as protecting group for the amine. We herein report 
Fmoc as protecting group for the N-terminus of the CPNA monomer with Cbz as the 
protecting group for the nucleobase and t-butyl ester for the carboxylic acid. This type of 
orthogonal protecting group strategy is required for the selective deprotection at the C-
terminus and N-terminus during solid phase synthesis. 
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                           Figure 15- Structure of Cysteine based PNA (CPNA) 
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Modification of this structure leads to formation of new a CPNA as shown below. 
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                                         Figure 16- Structure of modified CPNA 
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3.3-Synthesis of the monomer  
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                                  Figure 17- Synthesis of S-alkylated compounds 
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                            Figure 18- Synthesis of S-methyl monomer  
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                                 Figure 19- Synthesis of S-alkylated monomer 
 
Synthesis of CPNA monomer was done using commercially available starting material 
Boc(Cys)Trt-COOH. Literature survey reveals reductive amination as most common 
route for many scientists, but this route can lead to partial racemization. We avoid this 
potential problem. Compound 2a was made by using dicyclohexyl carbodiimide to 
activate the carboxylic acid. When all the carboxylic acid was activated, ammonium 
hydroxide was added to the reaction at 0 0C. Here the byproduct is N-N’-DCC urea. 
Other activating agent like DIC and EDC were also used. Triturating the crude reaction 
mixture gives pure compound but better yields were obtained by using column 
chromatography. 
   Reduction of amide 2a using BH3-THF complex gave amine 3a. Methanol was used as 
solvent to break borane complex at the end of reaction. The crude mixture was subjected 
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to water workup at pH=8.5. The free amine 3a was protected with Fmoc group by using 
1eq of Fmoc-Cl and 1.05eq of DIEA as base. Addition of Fmoc-Cl and base was done at 
0 0C and the reaction was warmed to room temperature. Although the reaction is 
straightforward purification using column chromatography was difficult, even flash silica 
gel could not enable separation. However trituration with ethyl acetate and hexane proved 
to be best solution for this problem and afforded compounds in good yield. 
      In order to synthesize compound 6a and 10a, TFA was used under dilute conditions at 
0 0C. The Boc and trityl groups are acid labile. However in dilute conditions, the trityl 
group is selectively removed. To this thiol 1eq of base was added followed by the 
alkylating agent. The Boc group was removed before N-alkylation; this was done by 
passing anhydrous HCl gas into the reaction mixture containing 1, 4-dioxane as solvent. 
The alkylation was done using tert-butyl bromoacetate and DIEA. The alkylating agent 
must be exactly 1eq as even a slight excess leads to formation of dialkylated product. 
This reaction was tried with different solvents but DMF proved to be the best keeping 
1Molar concentration of starting material in solution. 
       Monomer was synthesized from sub-monomer by base coupling reaction. Coupling 
of nucleobase using HATU and TEA as base did not work. Another strategy had to be 
applied wherein thymine acetic acid was refluxed at 55 0C in thionyl chloride for 2hr 
followed by concentration and sub-monomer 8a, 12a were added in DMF followed by 
TEA. This afforded successful base coupling reaction for thymine acetic acid. 
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Modified nucleobase was used to synthesize the monomer. The free amine is protected 
using Cbz group as it may cause side reactions during solid phase synthesis. Once the 
oligomer is synthesized the Cbz groups will be removed. The modification of nucleobase 
cytosine was done in three steps. In the first step, the NH2 was protected using Cbz-Cl in 
pyridine as solvent. The reaction was stirred for 3 days and filtered, the filtrate was the 
product. Compound 16a was synthesized from 15a by using tert-butyl bromoacetate and 
potassium carbonate. Compound 17a was synthesized by deprotection of t-butyl group 
using HCl in 1, 4-Dioxane.43 
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3.4- Experimental Procedures 
3.4.1.  Carbamic acid, [(1R)-2-amino-2-oxo-1-[[triphenylmethyl)thio]methyl] 
ethyl]-1,1-dimethylethyl ester, 2a.   To a solution of 1a (2 g, 4.31 mmol), HOBT (700 
mg, 5.18 mmol) and DCC (1.07 g, 5.18 mmol) in THF (10 ml) was added 28 % NH4OH 
(0.78 ml, 6.46 mmol) at 0 °C. After 2hr of stirring at 0 °C, the reaction mixture was 
filtered through celite and filtrate was concentrated, diluted with EtOAc, and washed with 
water and brine. Organic layer was then dried over sodium sulfate, concentrated and 
subjected to flash column chromatography to give 2a(1.95 g, 98 %) as a  white solid. 
 Rf = 0.51 (1:1 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3306.45, 
2977.8, 1676.78, 1490.10, 1392.02, 1366.78, 1249.95, 1164.94, 740.79, 699.77 cm-1. 1H 
NMR (250MHz, CDCl3) δ 7.46-7.38 (d, 6H), 7.23 (ddd, J=10.62, 5.16, 9H), 6.05 (s, 1H), 
5.95-5.82 (m, 1H), 4.94 (t, J=6.90Hz, 1H), 3.95-3.85 (m, 1H), 2.67 (dd, J=12.62 Hz), 
2.54 (dd, J=12.84 Hz, 1H),  1.41 (s, 9H). 13C (250MHz, CDCl3) δ 173.8, 155.42, 144.42, 
130.04, 129.60, 128.10, 126.93, 80.34, 67.24, 53.22, 33.80, 28.33. m/z 485.16 (M+Na)+ 
 
3.4.2.  (2-Amino-1-tritylsulfanylmethyl-ethyl)-carbamic acid tert-butyl ester, 
3a. To solution of 2a(1 g, 2.16 mmol) in anhy THF(5 ml) was added 1 M Borane·THF 
complex(5.4 ml, 5.4 mmol) at 0° C and after stirring at 0° C for 3 hrs,  the reaction 
mixture was then heated to 60°C and refluxed for 12 hrs. The reaction mixture was 
cooled to 0° C and quenched by MeOH, the reaction mixture was then concentrated and 
diluted with MeOH and concentrated again. The concentrated oil was then subjected to 
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water work-up pH-8.5 followed by flash column chromatography to afford 3a (0.58 mg, 
60 %). 
Rf = 0.28 (100% Ethyl acetate). IR (Nicolet Avatar 320 FTIR) νmax 3048.9, 2360.69, 
1706.97, 1489.75, 1445.10, 1365.46, 1265.58, 1167.82, 742.71, 700.29, 686.87 cm-1. 1H 
NMR (250MHz, CDCl3) δ 7.40 (d, J=7.27 Hz, 6H), 7.19 (ddd, J=14.29, 5.76 Hz, 9H), 
5.27-4.85 (br, 1H), 3.55 (br, 2H), 2.35 (tt, J=17.88, 8.99 Hz, 2H), 2.63 (d, J=5.68 Hz, 
2H), 1.39 (s, 9H). 13C (250MHz, CDCl3) δ 155.57, 144.65, 79.35, 66.79, 64.35, 60.39, 
44.40, 34.37. m/z 449.22 (M+H)+ 
 
3.4.3.  [2-(9H-Fluoren-9-ylmethoxycarbonylamino)-1-tritylsulfanyl)methyl-
ethyl]-carbamic acid tert-butyl ester, 4a. 
To a solution of  3a (0.1168 gm, 0.26 mmol) in DCM, Fmoc-Cl(70.7 mg, 0.273 mmol) 
was added followed by addition of DMAP(3.18 mg, 0.026 mmol) and DIPEA(0.043 ml, 
0.26 mmol)was added at 0° C and stirred for  3 h at room temperature. The reaction 
mixture was concentrated to give crude oil. The product 4a was obtained by triturating 
the crude oil with ethyl acetate and hexane (0.147 gm, 85 %). 
Rf = 0.5 (1:2 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3300.13, 
2977.61, 1697.26, 1518.36, 1447.66, 1366.39, 1247.71, 1164.98, 758.74, 739.49, 701.05 
cm-1. 1H NMR (250MHz, CDCl3) δ 7.74 (d, J=7.23 Hz, 2H), 7.55 (d, J=7.39 Hz, 2H), 
7.39 (t, J=7.59 Hz, 8H), 7.30-7.13 (m, 11H), 4.79-4.68 (m, 2H), 4.36 (d, J=6.64 Hz, 2H), 
4.17 (d, J=6.65 Hz, 1H), 3.65-3.48 (m, 1H), 3.12 (d, J=5.18 Hz, 2H), 2.30 (d, J=6.21 Hz, 
2H), 1.42 (s, 9H). 13C (250MHz, CDCl3) δ 156.89, 155.73, 144.56, 144.00, 143.96, 
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129.62, 128.06, 127.13, 125.10, 120.05, 79.70, 50.41, 47.31, 44.32, 34.05, 28.45. m/z 
671.28 (M+H)+ 
 
3.4.4.  [2-(9H-Fluoren-9-ylmethoxycarbonylamino)-1-mercaptomethyl-
ethyl]-carbamic acid tert-butyl ester, 5a. To a solution of 4a (62.9 mg, 0.093 mmol) in 
10ml DCM was added TES (12 mg, 0.103 mmol). The reaction mixture was cooled to 00 
C. TFA 0.5 ml was added dropwise. The reaction mixture was concentrated and subjected 
to flash column chromatography to afford 5a (39.5 mg, 98.8 %). 
Rf = 0.42 (1:2 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3341.02, 
2977.59, 1685.18, 1529.01, 1450.07, 1392.13, 1367.11, 1318.53, 1252.73, 1166.74, 
1006.71, 758.84, 740.47 cm-1. 1H NMR (250MHz, CDCl3) δ 7.75 (d, J=7.35 Hz, 2H), 
7.57 (d, J=7.39 Hz, 2H), 7.33 (ddd, J=18.25, 5.95 Hz, 4H), 5.29 (d, J=6.53 Hz, 2H), 4.40 
(d, J=6.52 Hz, 2H), 4.18 (t, J=6.66 Hz, 1H), 3.78 (d, J=4.61 Hz, 1H), 3.36 (dd, J=10.96 
Hz, 2H), 2.77-2.48 (m, 2H), 1.56 (t, J=8.75, 1H), 1.43 (s, 9H). 13C (250MHz, CDCl3) δ 
157.19, 155.94, 143.83, 141.34, 127.75, 127.09, 126.31, 120.02, 80.07, 66.91, 52.46, 
47.24, 43.07, 28.36. m/z 429.18 (M+H)+ 
 
3.4.5.  [2-(9H-Fluoren-9-ylmethoxycarbonylamino)-1-methylsulfanylmethyl-
ethyl]-carbamic acid tert-butyl ester, 6a. To a solution of 5a (0.8 gm, 1.86 mmol) in 
ethanol was added TBAI (6.9 mg, 0.186 mmol) at 0 0C. From 2N NaOH (0.93 ml, 1.86 
mmol) was added drop wise followed by drop wise addition of  Me-I (0.1746 ml, 2.79 
mmol) in ethanol. The reaction mixture was stirred for 3 hr and concentrated followed by 
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water work-up at pH=8.5.  The organic layer was dried over anhydrous sodium sulfate 
and concentrated followed by flash column chromatography gave 6a (0.727 gm, 88. %). 
Rf = 0.35 (1:2 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3343.45, 
2980.49, 1682.50, 1532.49, 1445.29, 1317.49, 1287.41, 1264.77, 1172.02, 1004.03, 
757.59, 740.41 cm-1. 1H NMR (250MHz, CDCl3) δ 7.75 (d, J= 7.35 Hz, 2H), 7.58 (d, 
J=7.26 Hz, 2H), 7.33 (ddd, J=17.60, 5.17 Hz, 4H), 5.36-5.26 (m, 1H), 5.15 (d, J=7.51 Hz, 
1H), 4.40 (d, J= 6.76 Hz, 2H), 4.21 (d, J=6.52 Hz, 1H), 3.89-3.72 (m, 1H), 3.51-3.26 (m, 
2H), 2.71-2.50(m, 2H), 2.13 (s, 2H), 1.43 (s, 9H). 13C (250MHz, CDCl3) δ 157.17, 
143.90, 141.33, 127.73, 127.09, 125.05, 120.0, 79.85, 66.88, 47.25, 44.09, 36.51, 28.39, 
16.16. m/z 465.18 (M+Na)+ 
 
3.4.6.  (2-Amino-3-methylsulfanyl-propyl)-carbamic acid 9H-fluoren-9-
ylmethyl ester, 7a. To a solution of 6a(0.727 gm, 1.64 mmol) in 1,4-dioxane at 0 oC 
hydrogen chloride gas was passed for 15 min and reaction was stirred at room 
temperature for 30 min. The reaction mixture was concentrated and kept in vacuum for 
drying gave 7a (0.562 gm, 100 %). 
IR (Nicolet Avatar 320 FTIR) νmax 2918.21, 1694.85, 1532.71, 1449.60, 1254.57, 758.78, 
737.48 cm-1. 1H NMR (250MHz, CDCl3) δ 7.65 (d, J=6.61 Hz, 4H), 7.33-7.17 (m, 4H), 
4.33-4.06 (m, 5H), 3.99-3.93 (m, 1H), 3.08-2.58 (m, 3H), 2.03 (s, 4H). 13C (250MHz, 
CDCl3) δ 157.28, 143.79, 141.20, 127.72, 127.15, 125.15, 125.41, 119.93, 67.35, 51.91, 
47.05, 42.43, 34.32, 15.95. m/z 343.14 (M+H)+ 
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3.4.7.  [2-9H-Fluoren-9-ylmethoxycarbonnylamino)-1-methylsulfanylmethyl-
ethylamino]-acetic acid tert-butyl ester, 8a. To a solution of 7a(0.562 gm, 1.486 mmol) 
in DMF was added tert-butyl bromoacetate (0.23 ml, 1.56 mmol) at 0°C followed by 
addition of DIPEA (0.515 ml, 3.12mmol) and tetra butyl ammonium iodide(55 mg, 0.148 
mmol). The reaction mixture was stirred for 3 hr. The reaction mixture was then  
concentrated and subjected to water work-up at pH=8.5 followed by drying with 
anhydrous sodium sulfate. Flash column chromatography gave 8a(0.449 gm, 60 %). 
Rf = 0.18 (1:2 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3313.15, 
2976.17, 1727.23, 1518.20, 1477.76, 1449.95, 1367.62, 1246.23, 1153.07, 759.28, 741.64 
cm-1. 1H NMR (400MHz, CDCl3) δ 7.76(d, J=7.48 Hz, 2H), 7.62 (d, J=7.44 Hz, 2H), 7.39 
( t, J=7.28 Hz, 2H), 7.31 (t, J=7.45 Hz, 2H), 7.26 (s, 1H), 5.57 (s, 1H), 5.29 (s, 1H), 4.42-
4.36 (m, 2H), 4.23 (d, J=7.02 Hz, 1H), 3.36 ( s, 2H), 3.33-3.25 (m, 2H), 2.82 (d, J=5.01 
Hz, 1H), 2.58 (dd, J=16.81 Hz, 2H), 2.11 (s, 2H), 1.48 (s, 9H). 13C (400MHz, CDCl3) δ 
172.03, 156.97. 144.23, 141.52, 127.86, 127.24, 125.35, 120.16, 81.82, 66.93, 49.43, 
43.28, 28.33, 16.21. m/z 457.21 (M+H)+ 
 
3.4.8.  {[2-9H-Fluoren-9-ylmethoxycarbonylamino)-1-methylsulfanylmethyl-
ethyl]-[2-(5-methyl-2,4-dioxo-3,4-dihydro-2Hpyrimidin-1-yl-acetyl]-amino}-acetic 
acid tert-butyl ester, 9a. 
To a solution of thionyl chloride 1.5 ml was added thymine acetic acid (0.173 gm, 
0.939mmol) the solution was refluxed at 60 oC for 3 hr under an atmosphere of nitrogen. 
The solution was concentrated and compound 8a (0.1435 gm, 0.314mmol) dissolved in 
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0.5 ml of DMF, followed by addition of DIEA (0.078 ml, 0.471mmol). The solution was 
refluxed at 55 oC for 2hr. The solution was concentrated and subjected to water workup 
with water and ethyl acetate. The organic layer was concentrated and subjected to flash 
column chromatography to give compound 9a (97.8 mg, 50%). 
Rf = 0.15 (1:1 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 3060.05, 
2926.15, 1672.01, 1522.05, 1450.64, 1370.04, 1324.59, 1246.16, 1152.04, 1080.95, 
910.32, 760.31, 740.28, 702.03 cm-1. 1H NMR (400MHz, CDCl3) δ 9.37-9.36 (m, 1H), 
7.76 (d, J=7.43 Hz, 2H), 7.63 (dd, J=7.20 Hz, 2H), 7.40 (t, J=7.41 Hz, 2H), 5.30 (s, 1H), 
4.70-4.62 (m, 1H), 4.36 (s, 2H), 4.28-4.20 (m, 4H), 4.16-4.10 (m, 3H), 4.06 (s, 2H), 3.51-
3.42 (m, 1H), 2.63 (d, J=7.06 Hz, 2H), 2.19 (s, 2H), 2.04 (s, 3H), 1.84 (s, 9H). 13C 
(400MHz, CDCl3) δ 175.33, 169.29, 156.71, 150.53, 144.09, 143.78, 141.46, 127.85, 
125.29, 120.01, 110.51, 83.99, 82.09, 57.70, 55.76, 42.39, 41.46, 35.86, 33.31, 21.19, 
19.12, 13.70. m/z 623.25 (M+H)+ 
 
3.4.9.  (1-[(3-Benzyloxycarbonylamino-propylcarbamoyl)-
methylsulfanylmethyl]-2-(9H-fluoren-9-ylmethoxycarbonyl amino)-ethyl]-carbamic 
acid tert-butyl ester, 10a. To a solution of 5a (31.2 mg, 0.0728 mmol) in ethanol was 
added TBAI (2.7 mg, 00728 mmol) at 0 oC. From 2N NaOH solution (0.036 ml, 0.0728 
mmol) was added drop-wise followed by drop-wise addition of R-Br (25.26 mg, 0.0765 
mmol) in ethanol. The reaction mixture was stirred for 3 hr and concentrated followed by 
water work-up at pH=8.5.  The organic layer was dried over anhydrous sodium sulfate 
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and concentrated followed by flash column chromatography gave 10a (0.0435 mg, 88.7 
%). 
Rf = 0.53 (100% Ethyl acetate). IR (Nicolet Avatar 320 FTIR) νmax 3320.81, 3064.27, 
2930.73, 1678.66, 1651.12, 1533.07, 1448.70, 1391.80, 1366.94, 1249.57, 1150.65, 
1065.28, 1003.67, 756.99, 736.50 cm-1. 1H NMR (250MHz, CDCl3) δ 7.74 (d, J=7.37 Hz, 
2H), 7.56 (d, J=7.33, 2H), 7.42-7.21 (m, 9H), 5.73 (dd, J=8.46 Hz, 1H), 5.51 (t, J=5.76 
Hz, 1H), 5.07 (d, J=7.26 Hz, 2H), 4.37 (d, J=6.79 Hz, 2H), 4.16 ( t, J=6.51 Hz, 1H), 3.39-
3.13 (m, 8H), 2.82-2.55(m, 2H), 2.21 (s, 1H), 2.03 (s, 1H), 1.70-1.60 (m, 2H), 1.40 (s, 
9H). 13C (250MHz, CDCl3) δ 169.40, 157.45, 143.86, 141.31, 136.51, 128.52, 128.12, 
128.05, 127.75, 127.08, 125.04, 120.01, 79.88, 66.88, 51.36, 47.21, 43.66, 37.87, 36.81, 
36.46, 35.21, 29.89, 29.09, 28.40. m/z 677.29 (M+H)+ 
 
3.4.10.  {2-Amino-3-[(3-benzyloxycarbonylamino-propylcarbamoyl)-
methylsulfanyl]-propyl}-carbamic acid9H-fluoren-9-ylmethyl ester, 11a. To a 
solution of 10a(1.16 g, 1.715 mmol) in 1,4-dioxane at 0 °C hydrogen chloride gas was 
passed for 15 min and reaction was stirred at room temperature for 30 min. The reaction 
mixture was concentrated and kept in vacuum for drying. 11a (1.05 gm, 100 %).  
IR (Nicolet Avatar 320 FTIR) νmax 3053.06, 1701.50, 1653.13, 1523.91, 1450.51, 
1264.47, 1120.71, 729.93, 700.64 cm-1. 1H NMR (250MHz, CDCl3) δ 8.64-8.38 (m, 2H), 
8.08-7.88 (m, 1H), 7.59 (s, 4H), 7.37-7.09 (m, 10H), 5.96-5.69 (m, 1H), 5.07-5.04 (m, 
1H), 4.96-4.89 (m,1H), 4.58-4.52 (m,1H), 4.29-3.88 (m, 4H), 3.31-3.01 (m, 5H), 1.68-
1.52 (m, 2H). 13C (250MHz, CDCl3) δ 170.88, 166.77, 157.51, 157.01, 143.73, 141.14, 
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137.49, 128.74, 128.59, 128.49, 128.40, 128.13, 127.87, 127.32, 119.96, 67.07, 66.74, 
52.19, 46.97, 46.29, 42.73, 38.37, 37.72, 36.63, 33.08. m/z 577.24 (M+H)+ 
 
3.4.11.  [1-[(3-Benzyloxycarbonylamino-propylcarbamoyl)-
methylsulfanylmethyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylamino]-
acetic acid tert-butyl ester, 12a. To a solution of 11a(1.05 gm, 1.715 mmol) in DMF 
was added tert-butyl bromoacetate (0.267 ml, 1.8 mmol) at 0°C followed by addition of 
DIPEA (0.595 ml, 3.6 mmol) and tetra butyl ammonium iodide(63.34 mg, 0.171 mmol). 
The reaction mixture was stirred for 3 hr. The reaction mixture was then  concentrated 
and subjected to water work-up at pH=8.5 followed by drying with anhydrous sodium 
sulfate, flash column chromatography to obtain 12a(0.71 gm, 60 %). 
Rf = 0.35 (100 Ethyl acetate). IR (Nicolet Avatar 320 FTIR) νmax 3332.82, 3068.60, 
1716.22, 1655.08, 1528.32, 1450.37, 1367.88, 1249.77, 1151.09, 1020.30, 759.39, 740.81 
cm-1. 1H NMR (400MHz, CDCl3) δ 7.74 (d, J=7.51 Hz, 2H), 7.59 (d, J=7.44 Hz, 2H), 
7.38 (t, J=7.45 Hz, 2H), 7.28 (dd, J=12.39 Hz, 6H), 5.86-5.78 (m, 1H), 5.44 (s, 1H), 5.06 
(s, 2H), 4.37 (d, J=6.91 Hz, 2H), 4.20 (d, J=6.88 Hz, 1H), 4.11 (d, J=7.17 Hz, 1H), 3.36-
3.24 (m, 6H), 3.22-3.17 (m, 4H), 2.87-2.78 (m, 1H), 2.75-2.56 (m, 2H), 2.03 (d, J=4.13 
Hz, 2H), 1.70-1.61 (m, 2H), 1.45 (s, 9H). 13C (400MHz, CDCl3) δ 172.22, 169.47, 
157.26, 144.15, 141.51, 136.75, 128.70, 128.28, 128.22, 127.89, 127.26, 125.31, 120.18, 
81.94, 66.92, 60.61, 49.37, 47.48, 43.27, 38.05, 36.64, 36.5, 36.26, 28.32. m/z 691.31 
(M+H)+ 
 38
3.4.12.  {[1-[(3-Benzyloxycardonylamino-propylcarbamoyl)-
methylsulfanylmethyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl-2-[(5-
methyl-2,4-dioxo-3,4-dihydro-2Hpyrimidin-1-yl)-acetyl]-amino} acetic acid tert-
butyl ester, 13a. 
To a solution of thionyl chloride 1.5 ml was added thymine acetic acid (0.104 gm, 
0.564mmol) the solution was refluxed at 60 oC for 3 hr under atmosphere of nitrogen. 
The solution was concentrated and compound 12a (0.1035 gm, 0.1499mmol) dissolved in 
0.5 ml of DMF was added, followed by addition of DIEA (0.037 ml, 0.224mmol). The 
solution was refluxed at 55 oC for 2hr. The solution was concentrated and subjected to 
water workup with water and ethyl acetate. The organic layer was concentrated and 
subjected to flash column chromatography to give compound 13a (64.2 mg, 50%). 
Rf = 0.5 (100% Ethyl acetate). IR (Nicolet Avatar 320 FTIR) νmax 3325.99, 2361.07, 
1700.50, 1673.81, 1533.16, 1452.49, 1372.57, 1250.96, 1152.64, 760.57, 740.24 cm-1. 1H 
NMR (400MHz, CDCl3) δ 9.59-9.52 (m, 1H), 7.81-7.73 ( m, 2H), 7.67-7.56 ( m, 2H), 
7.43-7.28 (m, 9H), 6.87-6.84 ( m, 1H), 6.66-6.59 (m, 1H), 5.45-5.39 (m, 1H), 5.31-5.27 
(m, 1H), 5.15-5.01 (m, 3H), 4.44-4.35 (m, 1H), 4.26-4.19 (m, 1H), 4.12 (d, J=7.15 Hz, 
2H), 3.23 (d, J=6.12 Hz, 8H), 2.77-2.71 (m, 1H), 2.04 (s, 2H), 1.77 (s, 4H), 1.75 (s, 9H). 
13C (400MHz, CDCl3) δ 171.15, 169.50, 164.22, 157.10, 155.60, 151.38, 128.77, 128.50, 
128.05, 127.97, 127.71, 127.67, 120.01, 112.06, 83.14, 67.01, 66.72, 61.02, 59.04, 47.20, 
44.64, 42.22, 37.91, 33.08, 30.79, 27.97, 14.22. m/z 857.35 (M+H)+ 
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3.4.13.  4-N-(Benzyloxycarbonyl)cytosine, 15a. Cytosine 14a (1 g, 9mmol) was 
added to pyridine (16 ml) along with DMAP (0.22 g, 1.8mmol). The reaction mixture 
was stirred for 5 min and benzyl chloroformate (2.83 ml, 19.8mmol) was added drop 
wise. After stirring at room temp for 3 days, 35 ml of ice cold water was added into the 
reaction mixture and stirred for 15 min and filtered and dried in vacuum at 50 oC to give 
white crystalline powder of 15a  (1.21 gm, 55 % ) 
IR (Nicolet Avatar 320 FTIR) νmax 1742.59, 1686.42, 1630.85, 1588.95, 1513.38, 
1472.37, 1320.0, 1230.8, 1202.91, 1076.28, 1005.71, 807.30, 742.07, 696.13 cm-1 . 1H 
NMR (250MHz, CDCl3) δ 11.18-11.00 (br, 1H), 7.80 (d, J=7.08 Hz, 1H), 7.39 (s, 5H), 
6.92 (d, J=7.02 Hz, 1H), 5.17 (s, 2H). 13C (400MHz, DMSO) δ 164.29, 156.50, 154.12, 
147.37, 136.7, 129.12, 128.78, 128.56, 94.18, 67.06. m/z 246.08 (M+H)+ 
 
3.4.14.  1-(tert-Butoxycarbonylmethyl)-4-N-(benzyloxycarbonyl)cytosine, 16a. 
To a suspension of 15(3 g, 12.25mmol) in anhydrous DMF (50 ml) was added anhydrous 
K2CO3 (1.69 gm, 12.22mmol) and anhydrous Cs2CO3 (0.4 gm, 1.22mmol). After stirring 
for 10 min tert-butyl bromoacetate (2.08 ml, 12.9mmol) was added dropwise and the 
mixture was stirred for 2 days. The resulting suspension was filtered, concentrated and 
subjected to a flash column chromatography to give 16a (1.625 gm, 37 %).   
Rf = 0.35 (3:1 :: Ethyl acetate/ Hexane). IR (Nicolet Avatar 320 FTIR) νmax 2983.2, 
2360.1, 1745.47, 1662.13, 1628.07, 1544.52, 1498.38, 1367.94, 1213.75, 1149.50, 
1062.56, 800.77, 785.62, 738.67, 694.04 cm-1. 1H NMR (250MHz, CDCl3) δ 8.42 (s, 1H), 
7.62 (d, J=7.27 Hz, 1H), 7.34 (s, 5H), 7.24 (d, J=6.66 Hz, 1H), 5.17 (s, 2H), 4.51 (s, 2H), 
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1.44 (s, 9H). 13C (250MHz, CDCl3) δ 166.66, 162.96, 155.59, 152.50, 149.39, 135.17, 
128.60, 128.26, 95.05, 83.11, 67.76, 51.49, 28.25. m/z 360.15 (M+H)+ 
 
3.4.15.  1-(Carboxymethyl)-4-N-(benzyloxycarbonyl)cytosine, 17a. 
To a suspension of 16 (1.5 gm, 2.925mmol) in anhydrous CH2Cl2 (5 ml) was added 4 N 
HCl in 1,4-dioxane (10 ml). The reaction was stirred for 16 hrs and partially concentrated 
in vacuum. Hexane (10 ml) was added to the mixture and the suspension was filtered. 
The residue was dried in vacuum at 60 0C to obtain 17a (1.265 gm, 100%) 
IR (Nicolet Avatar 320 FTIR) νmax 3081.49, 2505.5, 1714.89, 1633.28, 1611.12, 1547.94, 
1346.99, 1209.08, 1183.75, 1066.34, 847.20, 781.23, 726.24, 695.27 cm-1.  1H NMR 
(250MHz, CDCl3) δ 12.10-11.93 (br, 1H), 8.19 (d, J=6.73 Hz, 1H), 7.38 (d, J=11.65 Hz, 
5H), 7.06 (d, J=6.60 Hz, 1H), 5.21 (s, 2H), 4.60 (s, 2H). 13C (250MHz, DMSO) δ 168.98, 
162.45, 153.33, 152.67, 151.59, 135.63, 128.79, 128.47, 128.01, 94.00, 66.90, 50.59. m/z 
304.09 (M+H)+ 
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APPENDIX A:  1H AND 13C NMR SPECTRA 
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Spectrum 4.02 
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Spectrum 4.03 
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Spectrum 4.04 
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Spectrum 4.05 
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Spectrum 4.06 
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Spectrum 4.07 
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Spectrum 4.08 
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Spectrum 4.09 
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Spectrum 4.10 
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Spectrum 4.11 
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Spectrum 4.12 
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Spectrum 4.13 
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Spectrum 4.14 
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Spectrum 4.15 
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